Results 171 to 180 of about 75,755 (323)

Efficacy and safety of bi‐weekly cofrogliptin treatment replacing daily dipeptidyl peptidase‐4 inhibitors in Chinese patients with type 2 diabetes mellitus: A multicenter, open‐label, randomized controlled phase 2 trial

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1191-1200, February 2026.
Abstract Aim This study aimed to investigate the efficacy and safety of bi‐weekly cofrogliptin treatment as a replacement for daily dipeptidyl peptidase‐4 inhibitors (DPP‐4is) in Chinese patients with type 2 diabetes mellitus (T2DM). Methods This multicenter, open‐label, randomized controlled study assigned participants in a 1:1 ratio to either the ...
Congqing Pan   +10 more
wiley   +1 more source

Severity of complications is associated with impaired health‐related quality of life in people with type 1 diabetes

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1201-1212, February 2026.
Abstract Aims Health‐related quality of life (HRQoL) assessment is increasingly integrated into type 1 diabetes (T1D) monitoring to promote a holistic approach. To investigate HRQoL in adults with T1D and to assess the impact of the severity of complications on HRQoL.
Sara Barraud   +20 more
wiley   +1 more source

PIONEER REAL Saudi Arabia: A multicentre, prospective, real‐world study of once‐daily oral semaglutide use in adults with type 2 diabetes in Saudi Arabia

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1304-1314, February 2026.
Abstract Aim PIONEER REAL Saudi Arabia investigated real‐world clinical outcomes associated with the use of once‐daily oral semaglutide in adults with type 2 diabetes (T2D). Materials and Methods This was a 34‐ to 44‐week multicentre, prospective, open‐label study in adults with T2D, who were treatment‐naive to injectable glucose‐lowering medication ...
Hussein ElBadawi   +11 more
wiley   +1 more source

Safety and effectiveness of tirzepatide during Ramadan fasting: Real‐world evidence from patients with type 2 diabetes in Bangladesh

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1508-1516, February 2026.
Abstract Aims Ramadan fasting poses challenges for patients with type 2 diabetes mellitus (T2DM) due to increased risks of hypoglycemia and metabolic fluctuations. Tirzepatide, a dual GIP/GLP‐1 receptor agonist, has shown marked efficacy in glycemic control and weight reduction.
Muhammad Hafizur Rahman   +11 more
wiley   +1 more source

605 Euglycaemic Diabetic Ketoacidosis Complicating Cardiac Surgery [PDF]

open access: bronze, 2020
Michael McCann   +3 more
openalex   +1 more source

Home - About - Disclaimer - Privacy